Literature DB >> 1481726

Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats.

B C Toolan1, M Shea, E R Myers, R E Borchers, J G Seedor, H Quartuccio, G Rodan, W C Hayes.   

Abstract

Bisphosphonates inhibit osteoclast-mediated bone resorption, but their effects on the mechanical behavior of bone remain uncertain. This study investigated the effects of 4-amino-1-hydroxybutylidene bisphosphonate (AHBuBP) on the biomechanical and morphologic properties of bone in ovariectomized rats. Sprague-Dawley rats (four groups, n = 6) were ovariectomized at 3 months of age. From 7 to 13 months, the groups received vehicle or 0.28, 2.8, or 28 micrograms/kg of AHBuBP twice weekly through subcutaneous injection. An additional group of control animals (n = 6) received neither surgery nor drug. We determined the stiffness, yield, and ultimate loads of the femoral midshaft, the sixth lumbar (L6) vertebra, and the femoral neck. Geometric properties of the cortical bone were measured from digitized images of the tibial diaphysis at the level of the synostosis. The area fraction of trabecular bone was determined through the midsagittal plane of the fifth lumbar (L5) vertebra. There were no significant differences in the structural properties of the femoral neck and midshaft, with the exception that the medium-dose group had a greater ultimate load than the vehicle group for the femoral midshaft in bending. Cross-sectional analysis of the tibia did not show significant differences in the inertial properties or area. Ovariectomy caused a significant reduction in the stiffness and ultimate load of L6 and in the area fraction of trabecular bone of L5.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481726     DOI: 10.1002/jbmr.5650071207

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  21 in total

Review 1.  Bisphosphonates in the treatment of osteoporosis.

Authors:  N H Bell; R H Johnson
Journal:  Endocrine       Date:  1997-04       Impact factor: 3.633

Review 2.  Bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Eur Spine J       Date:  2003-09-16       Impact factor: 3.134

Review 3.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Hierarchical analysis and multi-scale modelling of rat cortical and trabecular bone.

Authors:  Ramin Oftadeh; Vahid Entezari; Guy Spörri; Juan C Villa-Camacho; Henry Krigbaum; Elsa Strawich; Lila Graham; Christian Rey; Hank Chiu; Ralph Müller; Hamid Nayeb Hashemi; Ashkan Vaziri; Ara Nazarian
Journal:  J R Soc Interface       Date:  2015-05-06       Impact factor: 4.118

5.  Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats.

Authors:  P Ammann; R Rizzoli; J M Meyer; J P Bonjour
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 6.  Preclinical pharmacology of alendronate.

Authors:  G A Rodan; J G Seedor; R Balena
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Authors:  S Adami; M C Baroni; M Broggini; L Carratelli; I Caruso; L Gnessi; M Laurenzi; A Lombardi; G Norbiato; S Ortolani
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

Review 8.  Rationale for the use of alendronate in osteoporosis.

Authors:  J A Kanis; B J Gertz; F Singer; S Ortolani
Journal:  Osteoporos Int       Date:  1995-01       Impact factor: 4.507

Review 9.  The role of bisphosphonates in the prevention and treatment of osteoporosis.

Authors:  J Y Reginster
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

10.  Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties.

Authors:  J A Guy; M Shea; C P Peter; R Morrissey; W C Hayes
Journal:  Calcif Tissue Int       Date:  1993-10       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.